At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 986 enrolled
Drug / intervention
Galcanezumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
In Brief
A Phase 3 clinical trial evaluating Galcanezumab and Placebo for Migraine. Completed, enrolled 986 participants across 113 sites in 12 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as galcanezumab in participants with episodic migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesArgentina, Czechia, Germany, Israel, Mexico, Netherlands, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartDec 2015
Primary CompletionMar 2017
Study CompletionOct 2018
TodayJul 2026
First PostedNov 25, 2015
Enrollment StartDec 4, 2015
Primary CompletionMar 29, 2017
Study CompletionOct 5, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.6 years ago
Interventions
Galcanezumabdrug
Administered SC
Placebodrug
Administered SC